PE20120315A1 - Una composicion farmaceutica que comprende candesartan, candesartan cilexetil, o azilsartan, combinado con amlodipino - Google Patents
Una composicion farmaceutica que comprende candesartan, candesartan cilexetil, o azilsartan, combinado con amlodipinoInfo
- Publication number
- PE20120315A1 PE20120315A1 PE2011001882A PE2011001882A PE20120315A1 PE 20120315 A1 PE20120315 A1 PE 20120315A1 PE 2011001882 A PE2011001882 A PE 2011001882A PE 2011001882 A PE2011001882 A PE 2011001882A PE 20120315 A1 PE20120315 A1 PE 20120315A1
- Authority
- PE
- Peru
- Prior art keywords
- esprotonous
- benzimidazole
- biphenyl
- methyl
- candesartan
- Prior art date
Links
- 229960000528 amlodipine Drugs 0.000 title abstract 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000005485 Azilsartan Substances 0.000 title 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 title 1
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 title 1
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 title 1
- 229960002731 azilsartan Drugs 0.000 title 1
- 229960000932 candesartan Drugs 0.000 title 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 title 1
- 229960004349 candesartan cilexetil Drugs 0.000 title 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- -1 BENZIMIDAZOLE COMPOUND Chemical class 0.000 abstract 2
- VVQNAFBGAWCMLU-UHFFFAOYSA-N 1h-benzimidazole-4-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=C1N=CN2 VVQNAFBGAWCMLU-UHFFFAOYSA-N 0.000 abstract 1
- NCUCGYYHUFIYNU-UHFFFAOYSA-N Aranidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1C1=CC=CC=C1[N+]([O-])=O NCUCGYYHUFIYNU-UHFFFAOYSA-N 0.000 abstract 1
- ZKFQEACEUNWPMT-UHFFFAOYSA-N Azelnidipine Chemical compound CC(C)OC(=O)C1=C(C)NC(N)=C(C(=O)OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZKFQEACEUNWPMT-UHFFFAOYSA-N 0.000 abstract 1
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- 239000004386 Erythritol Substances 0.000 abstract 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229950007556 aranidipine Drugs 0.000 abstract 1
- 229950004646 azelnidipine Drugs 0.000 abstract 1
- 150000001556 benzimidazoles Chemical class 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000019414 erythritol Nutrition 0.000 abstract 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 abstract 1
- 229940009714 erythritol Drugs 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 150000005846 sugar alcohols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009111381 | 2009-04-30 | ||
| JP2010068625 | 2010-03-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120315A1 true PE20120315A1 (es) | 2012-04-07 |
Family
ID=43032637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001882A PE20120315A1 (es) | 2009-04-30 | 2010-04-28 | Una composicion farmaceutica que comprende candesartan, candesartan cilexetil, o azilsartan, combinado con amlodipino |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP2424501A2 (zh) |
| JP (1) | JP5666471B2 (zh) |
| KR (1) | KR101797776B1 (zh) |
| CN (1) | CN102481248B (zh) |
| AU (1) | AU2010242308A1 (zh) |
| BR (1) | BRPI1014388A2 (zh) |
| CA (1) | CA2760073A1 (zh) |
| CL (1) | CL2011002662A1 (zh) |
| CO (1) | CO6470841A2 (zh) |
| CR (1) | CR20110581A (zh) |
| DO (1) | DOP2011000329A (zh) |
| EA (1) | EA201171329A1 (zh) |
| EC (1) | ECSP11011494A (zh) |
| GE (1) | GEP20135940B (zh) |
| IL (1) | IL215962A0 (zh) |
| MA (1) | MA33280B1 (zh) |
| MX (1) | MX2011011011A (zh) |
| MY (1) | MY158158A (zh) |
| NZ (1) | NZ596395A (zh) |
| PE (1) | PE20120315A1 (zh) |
| SG (1) | SG175794A1 (zh) |
| TW (1) | TWI438201B (zh) |
| WO (1) | WO2010126168A2 (zh) |
| ZA (1) | ZA201108375B (zh) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL236001B1 (pl) | 2012-12-21 | 2020-11-30 | Adamed Spolka Z Ograniczona Odpowiedzialnoscia | Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję |
| KR101535586B1 (ko) * | 2014-08-01 | 2015-07-09 | 에스케이케미칼주식회사 | 무정형 또는 열역학적 준 안정형 리바록사반을 포함하는 약학 제제 |
| WO2016122256A1 (ko) * | 2015-01-30 | 2016-08-04 | 씨제이헬스케어 주식회사 | 칸데사르탄 및 암로디핀을 포함하는 약제학적 조성물 |
| CN106668016B (zh) * | 2015-11-11 | 2020-06-23 | 江苏先声药业有限公司 | 阿齐沙坦和苯磺酸氨氯地平组合物的固体制剂及其制备方法 |
| JP2017210435A (ja) * | 2016-05-25 | 2017-11-30 | ダイト株式会社 | イルベサルタン及びアムロジピンベシル酸塩配合錠の製造方法 |
| JP2019001782A (ja) * | 2017-06-14 | 2019-01-10 | 東和薬品株式会社 | 二層錠 |
| JP7101464B2 (ja) * | 2017-09-28 | 2022-07-15 | エルメッド株式会社 | アジルサルタン又はその塩及びアムロジピン又はその塩含有錠剤の品質向上方法、並びにアジルサルタン又はその塩及びアムロジピン又はその塩含有錠剤及びその製造方法 |
| CN108210472A (zh) * | 2017-12-15 | 2018-06-29 | 蚌埠丰原医药科技发展有限公司 | 一种西尼地平固体分散体片剂及其制备方法 |
| CN108685925B (zh) * | 2018-05-15 | 2019-12-06 | 徐州医科大学 | 一种化合物AB-38b在制备治疗糖尿病肾病药物方面的应用 |
| JP2020075869A (ja) * | 2018-11-05 | 2020-05-21 | 日本ケミファ株式会社 | カルシウム拮抗剤及びアンジオテンシンｉｉ受容体拮抗剤を有効成分として含有する錠剤 |
| JP2020090471A (ja) * | 2018-12-07 | 2020-06-11 | ニプロ株式会社 | アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法 |
| JP7206872B2 (ja) * | 2018-12-07 | 2023-01-18 | ニプロ株式会社 | アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法 |
| JP7441105B2 (ja) * | 2020-03-31 | 2024-02-29 | 日本ジェネリック株式会社 | アジルサルタン及びアムロジピンベシル酸塩を含有するフィルムコーティング錠 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2814513B2 (ja) * | 1988-02-03 | 1998-10-22 | 吉富製薬株式会社 | 溶出性の改良された製剤組成物 |
| CA2125251C (en) * | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
| JP3057471B2 (ja) * | 1993-06-07 | 2000-06-26 | 武田薬品工業株式会社 | アンジオテンシンｉｉ介在性諸疾患の予防または治療剤 |
| EP1302462A4 (en) | 2000-07-17 | 2007-07-18 | Takeda Pharmaceutical | SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF |
| US20040121008A1 (en) * | 2001-03-16 | 2004-06-24 | Keiko Shiraishi | Process for producing sustained release preparation |
| CA2468827A1 (en) * | 2001-12-03 | 2003-06-12 | Takeda Chemical Industries, Ltd. | Insulin resistance improving agents |
| TW200306868A (en) * | 2002-05-22 | 2003-12-01 | Shionogi & Co | Composition of hardly soluble medicine with improved solubility |
| CA2507026A1 (en) | 2002-11-22 | 2004-06-10 | Takeda Pharmaceutical Company Limited | Imidazole derivatives, their production and use |
| EP1669352A4 (en) | 2003-09-30 | 2008-12-17 | Takeda Pharmaceutical | THIAZOLINE DERIVATIVE AND ITS USE |
| CA2550012A1 (en) | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | Urea derivative, process for producing the same and use |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| JP2006321726A (ja) * | 2005-05-17 | 2006-11-30 | Sysmex Corp | 錠剤の溶出性調整方法 |
| JP5063370B2 (ja) * | 2005-06-27 | 2012-10-31 | 第一三共株式会社 | 湿式造粒製薬の調製方法 |
| TWI405580B (zh) * | 2005-06-27 | 2013-08-21 | Sankyo Co | 含有血管收縮素ｉｉ接受器拮抗劑及鈣通道阻斷劑之醫藥調配物 |
| DE102005031577A1 (de) * | 2005-07-06 | 2007-01-11 | Bayer Healthcare Ag | Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten |
| CN104324015B (zh) * | 2007-03-29 | 2018-08-28 | 第一三共株式会社 | 药物组合物 |
| TW201014850A (en) * | 2008-09-25 | 2010-04-16 | Takeda Pharmaceutical | Solid pharmaceutical composition |
-
2010
- 2010-04-28 JP JP2011545129A patent/JP5666471B2/ja active Active
- 2010-04-28 PE PE2011001882A patent/PE20120315A1/es not_active Application Discontinuation
- 2010-04-28 BR BRPI1014388A patent/BRPI1014388A2/pt not_active IP Right Cessation
- 2010-04-28 GE GEAP201012480A patent/GEP20135940B/en unknown
- 2010-04-28 MX MX2011011011A patent/MX2011011011A/es not_active Application Discontinuation
- 2010-04-28 CA CA2760073A patent/CA2760073A1/en not_active Abandoned
- 2010-04-28 EA EA201171329A patent/EA201171329A1/ru unknown
- 2010-04-28 EP EP10719654A patent/EP2424501A2/en not_active Withdrawn
- 2010-04-28 SG SG2011078391A patent/SG175794A1/en unknown
- 2010-04-28 KR KR1020117027421A patent/KR101797776B1/ko active Active
- 2010-04-28 TW TW099113442A patent/TWI438201B/zh active
- 2010-04-28 AU AU2010242308A patent/AU2010242308A1/en not_active Abandoned
- 2010-04-28 MY MYPI2011005206A patent/MY158158A/en unknown
- 2010-04-28 WO PCT/JP2010/057923 patent/WO2010126168A2/en not_active Ceased
- 2010-04-28 MA MA34358A patent/MA33280B1/fr unknown
- 2010-04-28 NZ NZ596395A patent/NZ596395A/xx not_active IP Right Cessation
- 2010-04-28 CN CN2010800289702A patent/CN102481248B/zh not_active Expired - Fee Related
-
2011
- 2011-10-26 DO DO2011000329A patent/DOP2011000329A/es unknown
- 2011-10-26 CL CL2011002662A patent/CL2011002662A1/es unknown
- 2011-10-26 IL IL215962A patent/IL215962A0/en unknown
- 2011-11-08 CR CR20110581A patent/CR20110581A/es unknown
- 2011-11-15 ZA ZA2011/08375A patent/ZA201108375B/en unknown
- 2011-11-30 EC EC2011011494A patent/ECSP11011494A/es unknown
- 2011-11-30 CO CO11164599A patent/CO6470841A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2424501A2 (en) | 2012-03-07 |
| DOP2011000329A (es) | 2011-11-15 |
| CA2760073A1 (en) | 2010-11-04 |
| ECSP11011494A (es) | 2011-12-30 |
| CN102481248A (zh) | 2012-05-30 |
| CL2011002662A1 (es) | 2012-06-15 |
| TWI438201B (zh) | 2014-05-21 |
| CO6470841A2 (es) | 2012-06-29 |
| MX2011011011A (es) | 2011-11-02 |
| CR20110581A (es) | 2012-01-19 |
| EA201171329A1 (ru) | 2012-05-30 |
| IL215962A0 (en) | 2012-01-31 |
| AU2010242308A1 (en) | 2011-12-01 |
| SG175794A1 (en) | 2011-12-29 |
| GEP20135940B (en) | 2013-10-10 |
| JP2012525323A (ja) | 2012-10-22 |
| WO2010126168A3 (en) | 2011-03-03 |
| CN102481248B (zh) | 2013-12-11 |
| JP5666471B2 (ja) | 2015-02-12 |
| MA33280B1 (fr) | 2012-05-02 |
| KR20120026060A (ko) | 2012-03-16 |
| MY158158A (en) | 2016-09-15 |
| ZA201108375B (en) | 2013-01-30 |
| TW201041873A (en) | 2010-12-01 |
| KR101797776B1 (ko) | 2017-11-14 |
| NZ596395A (en) | 2013-06-28 |
| BRPI1014388A2 (pt) | 2016-04-05 |
| WO2010126168A2 (en) | 2010-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120315A1 (es) | Una composicion farmaceutica que comprende candesartan, candesartan cilexetil, o azilsartan, combinado con amlodipino | |
| PE20120018A1 (es) | Composicion farmaceutica de linagliptina y 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno, forma farmaceutica y procedimiento para su preparacion | |
| NZ594597A (en) | Substituted piperidines as ccr3 antagonists | |
| PE20120509A1 (es) | Derivados 9,9 difluoro-9h-fluoreno que tiene actividad antiviral | |
| CL2011000625A1 (es) | Preparación sólida que comprende 2-etoxi-1-((2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il)metil)-1h-bencimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metilo, un agente regulador de ph y un compuesto antagonista de calcio; y metodos para utilizar y mejorar disolucion del compuesto en la preparacion solida. | |
| PE20140934A1 (es) | Derivados de pirazol | |
| PE20142448A1 (es) | Compuestos de n-alquiltriazol como antagonistas de lpar | |
| AR065850A1 (es) | Composicion farmaceutica solida que comprende un derivado de benzimidazol-7-carboxilato y un agente de control de ph | |
| AR094588A2 (es) | Proceso de obtención de un compuesto derivado de benzimidazol y composición farmacéutica | |
| PE20080252A1 (es) | Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas | |
| CL2011002697A1 (es) | Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes | |
| PE20081315A1 (es) | Derivados de benzimidazol como antagonistas de vr-1 | |
| PE20080927A1 (es) | Derivados de benzoil-amino-heterociclilo como activadores de la glucoquinasa (glk) | |
| PE20142301A1 (es) | Uracilos sustituidos biciclicamente y uso de los mismos | |
| PE20091653A1 (es) | Derivados sustituidos de pirazol y su uso | |
| PE20130340A1 (es) | (r)-n-(3-(7-metil-1h-indazol-5-il)-1-(4-metilpiperidin-4-il)piperazin-1-il)-1-oxopropan-2-il)-4-(2-oxo-1,2-dihidroquinolin-3-il)piperidina-1-carboxamida como antagonista del receptor de peptido relacionado con el gen de la calcitonina (cgrp) | |
| CO6400144A2 (es) | Derivados aminoéster de alcaloides y composición medicinal de los mismos | |
| PE20090654A1 (es) | Formulaciones galenicas que contienen alisquireno y valsartan | |
| CL2011003371A1 (es) | Composicion farmaceutica de dosis fija, oral, solida y estable que comprende irbesartan, besilato de amlodipino y excipientes; procedimientos de preparacion; uso en el tratamiento de la hipertension. | |
| CR20110093A (es) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos | |
| AR065714A1 (es) | Sal clorhidrato de 5- (3-( 3- hidroxifenoxi ) azetidin- 1 - il ) - 5 - metil - 2, 2 - difenilhexanamida | |
| PE20091032A1 (es) | Composicion que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida (zibotentan) | |
| PL2021002T3 (pl) | Kompozycja farmaceutyczna zawierająca medoksomil olmesartanu | |
| PE20050762A1 (es) | Derivados de bencimidazol | |
| PE20110551A1 (es) | Composicion farmaceutica solida que contiene un derivado de bencimidazol y un diuretico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |